Drug Trial Radar · NCT05473156
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Jul 24, 2023
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- AP Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and antitumor activities of AP203 in adult patients with locally advanced or metastatic solid tumors.
Conditions
- Locally Advanced or Metastatic Solid Tumors
- Non Small Cell Lung Cancer (NSCLC)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
AP203Drug
Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D\[s\]). Participants will be administered by intravenous (IV) infusion, every week (Q1W \[± 1days\]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W \[± 3 days\]) for all the following doses.
AP203Drug
The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Escalation: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: The initial 28 days and completion of the first 4 doses of treatment
- Both Dose-Escalation and Dose-Expansion: Number of Participants With Adverse Events (AEs) and Serious AEsTime frame: At screening (≤ 28 days before the first dose of AP203), up to 90 days after the last dose
- Dose-Expansion: Overall response rate(ORR) (assessed by the Investigator according to RECIST version 1.1)Time frame: At screening (≤ 28 days before the first dose of AP203, up to 90 days after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AP Biosciences Inc.
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.